Bayer Presents New Research on Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension at 2015 ATS Annual Conference

Bayer Presents New Research on Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension at 2015 ATS Annual Conference

During the 2015 Annual International Conference of the American Thoracic Society (ATS), Bayer HealthCare is presenting recent research on chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). The conference is taking place in Denver between May 15 and 20.

Pulmonary Arterial Hypertension is a life-threatening condition characterized by blood pressure elevation in the pulmonary arteries, causing breathing difficulties, fatigue and dizziness. The condition can ultimately lead to heart failure.

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) causes blood clots and thromboembolic occlusion of the pulmonary vessels, and leads to an increase in pulmonary artery pressure.

“At the American Thoracic Society meeting, we will share Bayer’s recent, extensive research in the field of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, including new data from ongoing study of Adempas® (riociguat),” said Dario Mirski, MD, Vice President and Head, U.S. Medical Affairs at Bayer HealthCare Pharmaceuticals.

During the conference, Bayer will present these specific studies:

  • “Early Access Study (EAS) of Riociguat in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Baseline Characteristics and Comparison with Registry Data,” will be presented May 19th between 11:30am and 1:15 pm at the Colorado Convention Center; Area F, Hall A-B;
  • “Early Access Study (EAS) of riociguat in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Exploratory Interim Safety Assessment,” will be presented May 19th between 11:30 a.m. and 1:15 p.m. at the Colorado Convention Center; Area F, Hall A-B;
  • The poster titled “Characterization of Chinese Patients With Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Baseline Characteristics from the PATENT-1 and CHEST-1 Studies and Comparison With Other Studies,” will be presented May 19th between 11:30 a.m. and 1:15 p.m. at the Colorado Convention Center; Area F, Hall A-B;
  • An oral presentation titled “Efficacy and Safety of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Connective Tissue Disease: Results From PATENT-1 and PATENT-2,” was presented May 17th between 2:15 p.m. and 4:00 p.m. at the Colorado Convention Center; Bellco Theatre Section 1;
  • A poster titled “Health Outcome Assessment in Pulmonary Arterial Hypertension (PAH) Patients Treated with Riociguat: 2-Year Results from the PATENT-2 Long Term Extension Study,” will be presented May 19th between 11:30 a.m. and 1:15 p.m. at the Colorado Convention Center; Area F, Hall A-B;
  • The poster titled “ Health Outcome Assessment in Chronic Thromboembolic Pulmonary Hypertension (CTEPH)Patients Treated with Riociguat: 2-Year Results from the CHEST-2 Long Term Extension Study,” will be presented May 19th between 11:30 a.m. and 1:15 p.m. at the Colorado Convention Center; Area F, Hall A-B.

[adrotate group=”4″]

Bayer’s substantial involvement in presenting new research on PAH and CTEPH at this year’s ATS conference demonstrates the company’s recent efforts to develop new treatments for both diseases. This is an important development for PH patient populations, which are still confronted with serious unmet medical needs.

Leave a Comment

Your email address will not be published. Required fields are marked *